660 related articles for article (PubMed ID: 33748921)
1. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Kuemmel S; Tondini CA; Abraham J; Nowecki Z; Itrych B; Hitre E; Karaszewska B; Juárez-Ramiro A; Morales-Vásquez F; Pérez-García JM; Cardona-Huerta S; Monturus E; Sequi M; Restuccia E; Benyunes M; Martín M
Breast Cancer Res Treat; 2021 Jun; 187(2):467-476. PubMed ID: 33748921
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy de-escalation using an
Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
[TBL] [Abstract][Full Text] [Related]
5. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Bondarenko I; Paluch-Shimon S; Wardley A; Merot JL; du Toit Y; Easton V; Lindegger N; Miles D;
Ann Oncol; 2019 May; 30(5):766-773. PubMed ID: 30796821
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
7. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Takahashi M; Ohtani S; Nagai SE; Takashima S; Yamaguchi M; Tsuneizumi M; Komoike Y; Osako T; Ito Y; Ikeda M; Ishida K; Nakayama T; Takashima T; Asakawa T; Matsumoto S; Shimizu D; Masuda N
Breast Cancer Res Treat; 2021 Jan; 185(1):125-134. PubMed ID: 32920732
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Swain SM; Kim SB; Cortés J; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Knott A; Clark E; Ross G; Benyunes MC; Baselga J
Lancet Oncol; 2013 May; 14(6):461-71. PubMed ID: 23602601
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Xu B; Li W; Zhang Q; Li Q; Wang X; Li H; Sun T; Yin Y; Zheng H; Feng J; Zhu H; Siddiqui A; Macharia H; Knott A
Breast Cancer Res Treat; 2023 Feb; 197(3):503-513. PubMed ID: 36463547
[TBL] [Abstract][Full Text] [Related]
12. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D; Ciruelos E; Schneeweiss A; Puglisi F; Peretz-Yablonski T; Campone M; Bondarenko I; Nowecki Z; Errihani H; Paluch-Shimon S; Wardley A; Merot JL; Trask P; du Toit Y; Pena-Murillo C; Revelant V; Klingbiel D; Bachelot T;
Ann Oncol; 2021 Oct; 32(10):1245-1255. PubMed ID: 34224826
[TBL] [Abstract][Full Text] [Related]
13. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S; Harper-Wynne C; Park YH; Franke F; de Laurentiis M; Schumacher-Wulf E; Eiger D; Heeson S; Cardona A; Özyilkan Ö; Morales-Vàsquez F; Metcalfe C; Hafner M; Restuccia E; O'Shaughnessy J
BMC Cancer; 2024 May; 24(1):641. PubMed ID: 38789924
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
15. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
[TBL] [Abstract][Full Text] [Related]
16. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Swain SM; Ewer MS; Cortés J; Amadori D; Miles D; Knott A; Clark E; Benyunes MC; Ross G; Baselga J
Oncologist; 2013; 18(3):257-64. PubMed ID: 23475636
[TBL] [Abstract][Full Text] [Related]
17. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
